The future of targeted therapies
The partner-of-choice for targeted therapeutic delivery
Device-based Delivery: Extroducer®
The Extroducer is a novel, modality-agnostic endovascular infusion catheter with the ability to delivery payload directly to targeted cardiac and pancreatic tissues and solid tumors.
Cell Therapies
We are developing novel stem cell-based therapies for tissue repair in cardiac failure and Parkinsons’ disease using unique progenitor cell technology.
Modified Cell Therapies
We are currently investigating cell-mediated mRNA therapy technologies as we build out our targeted therapies portfolio.
We are
We are a drug delivery company pioneering innovative delivery solutions for targeted therapies
The main technology, the Extroducer®, is a modality-agnostic endovascular delivery device designed for localized delivery to hard-to-reach organs, tumors, and tissues. The Extroducer® is FDA 510(k)-cleared for use in peripheral (including abdominal) tissues to inject diagnostic and therapeutic solutions into the perivascular space.
Founded in 2014
Tullinge, Sweden
around 30 Employees
10 Nationalities
News & Updates from SmartCella
SmartCella inleder klinisk fas I/IIa studie med Extroducer® för riktad leverans av cytostatika vid bukspottkörtelcancer
SmartCella initiates Phase I/IIa clinical study with Extroducer® for targeted delivery of chemotherapy in pancreatic cancer
SmartCella och Oloker ingår licensavtal för Extroducer®, ett viktigt steg i strategin för riktade läkemedelsleveranser
Want to improve the targeting of your therapy?